Clinical trials: Neuron Disease, Motor
Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia
Therapy in Amyotrophic Lateral Sclerosis (TAME)
The purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their…
- Trial name
- TAME (NCT02118727)
- Testing
- Memantine
- Where
- 13 sites in United States
- Volunteers
- 89 people
- Sponsor
- University of Kansas Medical Center
Amyotrophic Lateral Sclerosis
Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis
The primary objective of the trial is to investigate the survival time (the time from randomization until death or end of the trial) compared between control group and experimental group.
- Trial name
- NCT01879241
- Testing
- Rasagiline
- Where
- 15 sites in Germany
- Volunteers
- 252 people
- Sponsor
- University of Ulm
Amyotrophic Lateral Sclerosis
The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.
Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is 3 years. Apart from Riluzole, there is no effective treatment.
- Trial name
- NCT04562831
- Testing
- EH301 (Nicotinamide Riboside/Pterostilbene)
- Where
- 9 sites in Norway
- Volunteers
- 380 people
- Sponsor
- Haukeland University Hospital
Amyotrophic Lateral Sclerosis
An In-home Study of Brain Computer Interfaces
The investigators are developing a tool to help people who are severely paralyzed. This tool is called a brain-computer interface (BCI). BCIs can connect to computers or other electronic devices.
- Trial name
- NCT01123200
- Testing
- Brain Computer Interface for Wheelchair Tilt Control
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan
Amyotrophic Lateral Sclerosis
Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS).
This study aims to evaluate safety and efficacy of tSMS in ALS patients and to obtain preliminary data about the effects of tSMS on cortical excitability.
- Trial name
- NCT04393467
- Testing
- tSMS
- Where
- 2 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Campus Bio-Medico University
Spinal Muscular Atrophy
Clinical Study of Spinal Muscular Atrophy
The investigators propose to prepare for clinical trials where SMA patients are asked to join the research effort. The visits will include questions, physical exam, blood drawing, and sometimes X-rays and a skin biopsy.
- Trial name
- NCT00443066
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Columbia University
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD).
- Conditions
- Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis, Myasthenia Gravis, Lambert-eaton Myasthenic Syndrome
- Trial name
- NCT07478172
- Testing
- Whole-body Electrical Muscle Stimulation Exercise
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Missouri-Columbia
Cerebral Palsy (CP), Spastic Diplegia Cerebral Palsy
Comparison of Synchronous and Asynchronous Action Observation Therapy in Children With Cerebral Palsy
The aim of this study is to compare the effects of synchronous and asynchronous action observation therapy (AOT) on balance, gait, and functional capacity in children with cerebral palsy (CP).
- Conditions
- Cerebral Palsy (CP), Spastic Diplegia Cerebral Palsy, Spastic Hemiplegic Cerebral Palsy, Neurodevelopmental Disorder (Diagnosis)
- Trial name
- NCT07114731
- Testing
- Synchronous Action Observation Therapy, Asynchronous Action Observation Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 22 people
- Sponsor
- Istanbul University - Cerrahpasa
Amyotrophic Lateral Sclerosis (ALS)
Study on the Safety and Efficacy of RAG-21 in the Treatment of Amyotrophic Lateral Sclerosis Patients With FUS Gene Mutations
Amyotrophic lateral sclerosis (ALS) is a chronic progressive neurodegenerative disease that remains incurable, with limited existing therapies or drugs available. Familial ALS can be caused by mutations in various genes.
- Trial name
- RAG-21-FUS-ALS (NCT07080801)
- Testing
- RAG-21
- Volunteers
- 6 people
- Sponsor
- Beijing Tiantan Hospital
Amyotrophic Lateral Sclerosis (ALS)
Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)
Use of noninvasive ventilation (NIV, also known colloquially as "Bipap") has been associated in some studies with improvement in pulmonary function, quality of life and survival.
- Trial name
- NCT01363882
- Testing
- Sleep study-guided adjustment of NIV, Standard initiation of NIV
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Columbia University
ALS, Amyotrophic Lateral Sclerosis
Speech Analysis in ALS Patients
The purpose of this study is to find out if changes in speech can signal changes in the ability to think or remember. ALS patients with and without cognitive dysfunction will be followed for one year.
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
- Trial name
- NCT03868345
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Barrow Neurological Institute
Amyotrophic Lateral Sclerosis
Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples
The purpose of the project is to obtain skin and adipose tissue samples from patients with ALS to develop new diagnostic and prognostic markers of the disease.
- Trial name
- ALS-TDI PEG (NCT01948102)
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Wake Forest University Health Sciences
Spinal Muscular Atrophy
Aerobic Training in Patients With Spinal Muscular Atrophy Type III
Spinal muscular atrophy type III, (SMAIII) is a disease in the nerve cells in the spinal cord which leads to to progressive muscle weakness and atrophy. No effective treatment is available for SMA.
- Trial name
- NCT02003937
- Testing
- Aerobic conditioning
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Amyotrophic Lateral Sclerosis
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is one of the most lethal neurodegenerative diseases, with most patients dying from respiratory failure 3-5 years after the onset.
- Trial name
- NATURAL (NCT06391645)
- Testing
- Nerve Growth Factor
- Volunteers
- 60 people
- Sponsor
- Beijing Tiantan Hospital
Prostate Cancer
An Open Label Prostate Cancer Study in Japanese Patients
The primary aim of study is to gain an initial assessment of safety and tolerability of AZD3514 in Japanese patients together with assessing Pharmacokinetics (PK) and gaining a preliminary assessment of anti-tumour action.
- Trial name
- NCT01351688
- Testing
- AZD3514
- Where
- 2 sites in Japan
- Volunteers
- 13 people
- Sponsor
- AstraZeneca
Amyotrophic Lateral Sclerosis (ALS)
Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients
Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron diseases. It is considered as a rare disease with a prevalence of about 8 per 100,000 persons.
- Trial name
- NCT02424669
- Testing
- ALS Functional rating Scale-revised (ALS FRS-R), slow vital capacity, Blood sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Metastatic Cancer, Congestive Heart Failure
Reducing Disparities in the Quality of Advance Care Planning for Older Adults
This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community.
- Conditions
- Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease
- Trial name
- EQUALACP (NCT03516994)
- Testing
- Respecting Choices First Steps, Five Wishes Form
- Where
- 4 sites in United States
- Volunteers
- 790 people
- Sponsor
- Duke University
ALS, Amyotrophic Lateral Sclerosis
A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)
This study will look at whether Pimozide may help to slow the progression of Amyotrophic Lateral Sclerosis. 100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2…
- Trial name
- Pimozide2 (NCT03272503)
- Testing
- Pimozide 2mg/day (current) or 4 mg/day (study initiation)
- Where
- 9 sites in Canada
- Volunteers
- 100 people
- Sponsor
- University of Calgary
Libido, Receptors, Androgen
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women
It is known that with increasing age sexual desire is declining in women. Decreasing levels of androgens are believed to have an influence, but cannot explain the loss of libido completely.
- Conditions
- Libido, Receptors, Androgen, Polymorphism, Genetic, Androgen Effect
- Trial name
- CAG-Libido (NCT01977313)
- Where
- Switzerland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Amyotrophic Lateral Sclerosis
Intermuscular Coherence as a Biomarker for ALS
The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS.
- Trial name
- ALS-IMC (NCT05104710)
- Where
- 4 sites in United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- University of Chicago
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.